MX2022007947A - Derivado de amida de acido alifatico. - Google Patents
Derivado de amida de acido alifatico.Info
- Publication number
- MX2022007947A MX2022007947A MX2022007947A MX2022007947A MX2022007947A MX 2022007947 A MX2022007947 A MX 2022007947A MX 2022007947 A MX2022007947 A MX 2022007947A MX 2022007947 A MX2022007947 A MX 2022007947A MX 2022007947 A MX2022007947 A MX 2022007947A
- Authority
- MX
- Mexico
- Prior art keywords
- sup
- sub
- acid amide
- aliphatic acid
- amide derivative
- Prior art date
Links
- -1 Aliphatic acid amide Chemical class 0.000 title 1
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 abstract 8
- 150000001875 compounds Chemical class 0.000 abstract 3
- 229940076279 serotonin Drugs 0.000 abstract 2
- 125000000217 alkyl group Chemical group 0.000 abstract 1
- 239000005557 antagonist Substances 0.000 abstract 1
- 125000002619 bicyclic group Chemical group 0.000 abstract 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 abstract 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 1
- 229910052757 nitrogen Inorganic materials 0.000 abstract 1
- 125000004433 nitrogen atom Chemical group N* 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
- C07D261/20—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings condensed with carbocyclic rings or ring systems
Abstract
La presente invención se refiere a un compuesto representado por la fórmula (1) (ver Fórmula), teniendo el compuesto actividad antagonista contra los receptores de serotonina 5-HT2A y los receptores de serotonina 5-HT7; o una sal farmacéuticamente aceptable del compuesto; (en la fórmula, Z es un átomo de nitrógeno y similares; Y es carbonilo y similares; m y n son 1 y similares; R1a a R1d, R2a a R2d, y R4a a R4d son átomo de hidrógeno y similares; R3 es alquilo y similares; y Q es un grupo bicíclico específico).
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2019232927 | 2019-12-24 | ||
PCT/JP2020/048117 WO2021132311A1 (ja) | 2019-12-24 | 2020-12-23 | 脂肪族酸アミド誘導体 |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2022007947A true MX2022007947A (es) | 2022-07-27 |
Family
ID=76574184
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2022007947A MX2022007947A (es) | 2019-12-24 | 2020-12-23 | Derivado de amida de acido alifatico. |
Country Status (11)
Country | Link |
---|---|
US (2) | US20220213079A1 (es) |
EP (1) | EP4082616A4 (es) |
JP (1) | JPWO2021132311A1 (es) |
KR (1) | KR20220120625A (es) |
CN (1) | CN114981264A (es) |
AU (1) | AU2020413284A1 (es) |
BR (1) | BR112022011844A2 (es) |
CA (1) | CA3161806A1 (es) |
MX (1) | MX2022007947A (es) |
TW (1) | TW202136235A (es) |
WO (1) | WO2021132311A1 (es) |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4880930A (en) * | 1987-11-30 | 1989-11-14 | New James S | Psychotropic acyclic amide derivatives |
EP0732332B1 (en) * | 1995-03-17 | 2001-12-19 | Aventis Pharmaceuticals Inc. | Substituted benzothienylpiperazines, their use as medicaments, and processes for their preparation |
US5880121A (en) * | 1996-01-05 | 1999-03-09 | Hoechst Marion Roussel Inc. | 4,5-dihydronaphth (1,2-c) isoxazoles and derivatives thereof |
JP4497815B2 (ja) * | 2001-02-16 | 2010-07-07 | アベンティス・ファーマスーティカルズ・インコーポレイテツド | 新規な複素環式アミド誘導体およびドーパミンd3受容体リガンドとしてのその使用 |
FR2827287B1 (fr) * | 2001-07-13 | 2003-10-31 | Servier Lab | Nouveaux derives de benzene sulfonamide, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
BR0316108A (pt) * | 2002-11-08 | 2005-09-27 | Warner Lambert Co | Derivados de fenilalquil e piridilalquil piperazina e composição farmacêutica compreendendo os mesmos |
ATE461925T1 (de) | 2005-04-26 | 2010-04-15 | Hypnion Inc | Benzisoxazolpiperidinverbindungen und verfahren zu deren anwendung |
PL392436A1 (pl) * | 2010-09-17 | 2012-03-26 | Adamed Spółka Z Ograniczoną Odpowiedzialnością | Pochodne arylosulfonamidów do leczenia chorób odśrodkowego układu nerwowego |
WO2014079155A1 (zh) * | 2012-11-26 | 2014-05-30 | 辽宁贝雷生物制药有限公司 | 苯并五元氮杂环基哌嗪或哌啶衍生物的用途 |
-
2020
- 2020-12-23 JP JP2021567520A patent/JPWO2021132311A1/ja active Pending
- 2020-12-23 AU AU2020413284A patent/AU2020413284A1/en active Pending
- 2020-12-23 WO PCT/JP2020/048117 patent/WO2021132311A1/ja unknown
- 2020-12-23 EP EP20907330.3A patent/EP4082616A4/en active Pending
- 2020-12-23 CN CN202080089588.6A patent/CN114981264A/zh active Pending
- 2020-12-23 MX MX2022007947A patent/MX2022007947A/es unknown
- 2020-12-23 KR KR1020227025336A patent/KR20220120625A/ko unknown
- 2020-12-23 TW TW109145718A patent/TW202136235A/zh unknown
- 2020-12-23 CA CA3161806A patent/CA3161806A1/en active Pending
- 2020-12-23 BR BR112022011844A patent/BR112022011844A2/pt unknown
- 2020-12-23 US US17/612,099 patent/US20220213079A1/en active Pending
-
2021
- 2021-11-17 US US17/528,743 patent/US11339151B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
WO2021132311A1 (ja) | 2021-07-01 |
US11339151B2 (en) | 2022-05-24 |
KR20220120625A (ko) | 2022-08-30 |
JPWO2021132311A1 (es) | 2021-07-01 |
US20220213079A1 (en) | 2022-07-07 |
EP4082616A1 (en) | 2022-11-02 |
US20220073506A1 (en) | 2022-03-10 |
CA3161806A1 (en) | 2021-07-01 |
AU2020413284A1 (en) | 2022-08-18 |
CN114981264A (zh) | 2022-08-30 |
EP4082616A4 (en) | 2024-01-03 |
TW202136235A (zh) | 2021-10-01 |
BR112022011844A2 (pt) | 2022-08-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2019012336A (es) | Compuestos inhibidores del transportador vesicular de monoaminas 2 (vmat2) y composiciones de los mismos. | |
IN2012CN09242A (es) | ||
RU2012126129A (ru) | Производное индола и его фармацевтическое применение | |
EA200701583A1 (ru) | Гетероциклические тетрациклические производные гидрофурана в качестве ингибиторов 5нт2 в терапии расстройств цнс | |
EA200701640A1 (ru) | Новые соединения с терапевтическим эффектом | |
EA200400981A1 (ru) | Новые гетероциклические соединения, активные в качестве ингибиторов бета-лактамаз | |
MY141559A (en) | Triazole derivatives as tachykinin receptor antagonists | |
MX2009004910A (es) | Compuestos sustituidos de 3-isobutil-9,10-dimetoxi-1,3,4,6,7,11-b- hexahidro-2h-pirido[2,1-a] isoquinolin-2-ol y métodos que se relacionan al mismo. | |
HK1071366A1 (en) | Compounds which inhibit the release of inflammatory cytokines | |
AR047076A1 (es) | Compuestos de pirrolotriazina como inhibidores de tirosina quinasas, composiciones farmaceuticas | |
MX2015008971A (es) | Derivados de pirimidina pirido- o pirrolo-fusionados como inhibidores de autotaxina para tratar dolor. | |
TW200745058A (en) | MMP-13 selective inhibitors | |
UA108510C2 (en) | Cyclopropane compound | |
MY193597A (en) | Novel pyrrolidine compound and application as melanocortin receptor agonist | |
PH12017501655B1 (en) | Morphinan derivative | |
EA200601178A1 (ru) | Морфолинилсодержащие бензимидазолы в качестве ингибиторов репликации респираторно-синцитиального вируса | |
ZA202108263B (en) | Imidazolonylquinoline compounds and therapeutic uses thereof | |
SG11201810725WA (en) | Novel β-lactamase inhibitors | |
JOP20220084A1 (ar) | مشتقات 5-أوكسا- 2- آزا سبيرو [3.4] أوكتان كناهضات لـ m4 | |
MX2022007947A (es) | Derivado de amida de acido alifatico. | |
IN2013MN00506A (es) | ||
JOP20220082A1 (ar) | مشتقات 2- آزا سبيرو [3.4] أوكتان كناهضات لـ m4 | |
AU2003257433A8 (en) | Substituted 4-phenyl-piperidin-amides as tachykinin antagonists and serotonin reptake inhibitors | |
MX2023003245A (es) | Derivados de amina novedosos. | |
MX2023006176A (es) | Nuevos derivados de indazol acetileno. |